Environmental toxicants, epigenetics, and cancer

Advances in Experimental Medicine and Biology

Volumn 754, Issue , 2013, Pages 215-232

  Pogribny, Igor P ^a   Rusyn, Ivan ^b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE; AFLATOXIN B1; ARSENIC; BIOLOGICAL PRODUCT; CARCINOGEN; DIETHYLSTILBESTROL; FUMONISIN B1; MYCOTOXIN; OXAZEPAM; PHENOBARBITAL; TAMOXIFEN;

CANCER CELL; CANCER RISK; CARCINOGENESIS; DISEASE MARKER; ENDOMETRIUM CANCER; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE MUTATION; GENOTOXICITY; HELICOBACTER INFECTION; HERITABILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN; OCCUPATIONAL EXPOSURE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 84869046076     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-9967-2_11     Document Type: Review

References (145)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer. Cell 144:646-674
2. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692 (Pubitemid 46273572)
3. Ushijima T, Asada K (2010) Aberrant DNA methylation in contrast with mutations. Cancer Sci 101:300-305
4. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27-36
5. Marlowe J, Teo SS, Chibout SD, Pognan F, Moggs JJ (2009) Mapping the epigenome - impact for toxicology. EXS 99:259-288
6. Kim JK, Samaranayake M, Pradhan S (2009) Epigenetic mechanisms in mammals. Cell Mol Life Sci 66:596-612
7. Ooi SK, O'Donnell AH, Bestor TH (2009) Mammalian cytosine methylation at a glance. J Cell Sci 122:2787-2791
8. Chen ZX, Riggs AD (2011) DNA methylation and demethylation in mammals. J Biol Chem 286:18347-18353
9. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074-1080 (Pubitemid 32758077)
10. Kouzarides T (2007) Chromatin modi fi cations and their function. Cell 128:693-705 (Pubitemid 46273577)
11. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148-1159
12. Pogribny IP, Beland FA (2009) DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 66:2249-2261
13. Ooi SK, Bestor TH (2008) The colorful history of active DNA demethylation. Cell 133:1145-1148 (Pubitemid 351852922)
14. Ma DK, Guo JU, Ming GL, Song H (2009) DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. Cell Cycle 8:1526-1531
15. He YF, Li BZ, Li Z, Wang Y, Tang Q, Ding J, Jiz Y, Chen Z, Li L, Sun Y, Li X, Dai Q, Song CX, Zhang K, He C, Xu GL (2011) Tet-mediated formation of 5-hydroxylcytosine and its excision by TDG in mammalian DNA. Science 333:1303-1307
16. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333: 1300-1333
17. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, Le Coz M, Devarajan K, Wessels A, Soprano D, Abramowitz LK, Bartolomei MS, Rambow F, Bassi MR, Bruno T, Fanciulli M, Renner C, Klein-Szanto AJ, Matsumoto Y, Kobi D, Davidson I, Alberti C, Larue L, Bellacosa A (2011) Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146:67-79
18. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143-153 (Pubitemid 38198742)
19. Ehrlich M (2009) DNA hypomethylation in cancer cells. Epigenomics 1:239-259
20. Wilson AS, Power BE, Molloy PL (2007) DNA hypomethylation and human diseases. Biochim Biophys Acta 1775:138-162 (Pubitemid 44881198)
21. De Smet C, Loriot A (2010) DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey. Epigenetics 5:206-213
22. Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, Ju J, Bestor TH (2006) Large-scale structure of genomic methylation patterns. Genome Res 16:157-163 (Pubitemid 43200263)
23. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395:89-93 (Pubitemid 28420236)
24. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400-5413 (Pubitemid 34983477)
25. Feinberg AP, Cui H, Ohlsson R (2002) DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 12:389-398
26. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A (2008) Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27:404-408
27. Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300:455 (Pubitemid 36444319)
28. Wong NC, Wong LH, Quach JM, Canham P, Craig JM, Song IZ, Clark SJ, Choo KH (2006) Permissive transcriptional activity at the centromere through pockets of DNA hypomethylation. PLoS Genet 2:e17
29. Vera E, Canela A, Fraga MF, Esteller M, Blasco MA (2008) Epigenetic regulation of telomeres in human cancer. Oncogene 27:6817-6833
30. Wild L, Flanagan JM (2010) Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim Biophys Acta 1806:50-57
31. Wainfan E, Poirier LA (1992) Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res 52:2071s-2077s
32. Christman JK (1995) Dietary effects on DNA methylation: do they account for hepatocarcinogenic properties of lipotrope diets? Adv Exp Med Biol 369:141-154
33. Pogribny IP, James SJ, Jernigan S, Pogribna M (2004) Genomic hypomethylation is speci fi c for preneoplastic liver in folate/methyl deficient rats and does not occur in non-target tissues. Mutat Res 548:53-59 (Pubitemid 38446881)
34. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R (2003) Induction of tumors in mice by genomic hypomethylation. Science 300:489-492 (Pubitemid 36444330)
35. Fan T, Schmidtmann A, Xi S, Briones V, Zhu H, Suh HC, Gooya J, Keller JR, Xu H, Roayaei J, Anver M, Ruscetti S, Muegge K (2008) DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development. Epigenetics 3:134-142
36. Counts JL, Goodman JI (1994) Hypomethylation of DNA: an epigenetic mechanism involved in tumor promotion. Mol Carcinog 11:185-188
37. Wild L, Funes JM, Boshoff C, Flanagan JM (2010) In vitro transformation of mesenchymal stem cells induces gradual genomic hypomethylation. Carcinogenesis 31:1854-1862
38. Bagnyukova TV, Tryndyak VP, Montgomery B, Churchwell MI, Karpf AR, James SR, Muskhelishvili L, Beland FA (2008) Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylamino fl uorene. Carcinogenesis 29:638-646 (Pubitemid 351404882)
39. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, Jaenish R (2005) Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 102:13580-13585 (Pubitemid 41420891)
40. Tomita H, Hirata A, Yamada Y, Hata K, Oyama T, Mori H, Yamashita S, Ushijima T, Hara A (2010) Suppressive effect of global DNA hypomethylation on gastric carcinogenesis. Carcinogenesis 31:1627-1633
41. Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, Karpf AR (2010) Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol Cell Biol 30:4159-4174
42. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shchors K, Heine VM, Rowitch DH, Xing X, Fiore C, Schillebeeckx M, Jones SJM, Haussler D, Marra MA, Hirst M, Wang T, Costello JF (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466:253-257
43. Takai D, Jones PA (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99:3740-3745 (Pubitemid 34252176)
44. Illingworth RS, Bird AP (2009) CpG islands - "a rough guide". FEBS Lett 583:1713-1720
45. Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Genes Dev 25:1010-1022
46. Jacinto FV, Esteller M (2007) Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22:247-253 (Pubitemid 47216613)
47. Lahtz C, Pfeifer GP (2011) Epigenetic changes of DNA repair genes in cancer. J Mol Cell Biol 3:51-58
48. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368-2371 (Pubitemid 30262424)
49. Esteller M, Riques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB, Herman JG (2001) Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is associated with the presence G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 61:4689-4692 (Pubitemid 32691877)
50. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjorf JE (2006) Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8:R38
51. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870-6875 (Pubitemid 28278073)
52. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Lyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400
53. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215-233
54. Carthew RW, Sontheimer EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136:642-655
55. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835-840
56. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in cancer. Annu Rev Med 60:167-179
57. Ventura A, Jacks ST (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136:586-591
58. Di Leva G, Croce CM (2010) Roles of small RNAs in tumor formation. Trends Mol Med 16:257-267
59. Pogribny IP (2009) MicroRNA dysregulation during chemical carcinogenesis. Epigenomics 1:281-290
60. Loeb LA, Harris CC (2008) Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res 68:6863-6872
61. Wild CP (2009) Environmental exposure measurement in cancer epidemiology. Mutagenesis 24:117-125
62. Clapp RW, Jacobs MM, Loechler EL (2008) Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 23:1-37 (Pubitemid 351644506)
63. Miller JA (1970) Carcinogenesis by chemicals: and overview - G.H.A. Clowes memorial lecture. Cancer Res 30:559-576
64. Herceg Z (2007) Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22:91-103 (Pubitemid 46364521)
65. Pogribny IP, Rusyn I, Beland FA (2008) Epigenetics aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents. Environ Mol Mutagen 49:9-15 (Pubitemid 351293008)
66. Bollati V, Baccareli A (2010) Environmental epigenetics. Heredity 105:105-112
67. Nakajima T, Enomoto S, Ushijima T (2008) DNA methylation: a marker for carcinogen exposure and cancer risk. Environ Health Prev Med 13:8-15
68. Ziech D, Franco R, Pappa A, Malamou-Mitsi V, Georgakila S, Georgakitas AG, Panayiotidis MI (2010) The role of epigenetics in environmental and occupational carcinogenesis. Chem Biol Interact 188:340-349
69. Hughes MF, Beck BD, Chen Y, Lewis AS, Thomas DJ (2011) Arsenic exposure and toxicology: a historical perspective. Toxicol Sci 123:305-332
70. Rossman TG (2003) Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 533:37-65 (Pubitemid 37487860)
71. IARC Monographs on the Evaluations of Carcinogenic Risks to Humans (2004) Some drinking- water disinfectants and contaminants, including arsenic, vol 84. IARC, Lyon
72. Liu J, Waalkes MP (2008) Liver is a target of arsenic carcinogenesis. Toxicol Sci 105:24-32
73. Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S (2006) Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4A and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci 91:372-381 (Pubitemid 43827290)
74. Waalkes MP, Ward JM, Liu J, Diwan BA (2003) Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol Appl Pharmacol 186:7-17 (Pubitemid 36266687)
75. Tokar EJ, Diwan BA, Ward JM, Delker DA, Waalkes MP (2011) Carcinogenic effects of "whole-life" exposure to inorganic arsenic in CD1 mice. Toxicol Sci 119:73-83
76. Reichard JF, Puga A (2010) Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics 2:87-104
77. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP (1997) Association of arsenicinduced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 94:10907-10912 (Pubitemid 27430834)
78. Chen H, Li S, Liu J, Diwan BA, Barrett JC, Waalkes MP (2004) Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 25(9):1779-1786 (Pubitemid 39214321)
79. Jensen TJ, Novak P, Elbin KE, Gandol fi AJ, Futscher BW (2008) Epigenetic remodeling during-arsenical-induced malignant transformation. Carcinogenesis 29:1500-1508
80. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L (2011) An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect 119:11-19
81. Coppin JF, Qu W, Waalkes MP (2008) Interplay between cellular methyl metabolism and adaptive ef fl ux during oncogenic transformation from chronic arsenic exposure in human cells. J Biol Chem 283:19342-19350
82. Kitchin KT, Ahmad S (2003) Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol Lett 137:3-13 (Pubitemid 36044037)
83. Kojima C, Ramirez DC, Tokar EJ, Himeno S, Drobná Z, Stýblo M, Mason RP, Waalkes MP (2009) Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst 101:1670-1681
84. Valinluck V, Sowers LC (2007) Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 67:946-950
85. Lee DH, Jacobs DR Jr, Porta M (2009) Hypothesis: a unifying mechanism for nutrition and chemicals as lifelong modulators of DNA hypomethylation. Environ Health Perspect 117:1799-1802
86. Mass MJ, Wang L (1997) Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 386:263-277 (Pubitemid 27286299)
87. Huang YC, Huang WC, Chen WT, Yu HS, Chai CY (2009) Sodium arsenite-induced DAPK hypermethylation and autophagy via ERK1/2 phosphorylation in human uroepithelial cells. Chem Biol Interact 181:254-262
88. Zhou X, Sun H, Ellen TP, Chen H, Costa M (2008) Arsenite alters global histone H3 methylation. Carcinogenesis 29:1831-1836
89. Beezhold K, Liu J, Kan H, Meighan T, Castranova V, Shi X, Chen F (2011) miR-190-mediated downregulation of PHLP contributes to arsenic-induced Akt activation and carcinogenesis. Toxicol Sci 123(2):411-420
90. Salnikow K, Zhitkovich A (2008) Genetic and epigenetic mechanisms in metals carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res Toxicol 21:28-44 (Pubitemid 351219706)
91. Martinez-Zamudio R, Ha HC (2011) Environmental epigenetics in metal exposure. Epigenetics 6(7):820-827
92. IARC Monographs on the Evaluations of Carcinogenic Risks to Humans (2008) 1,3-Butadiene, ethylene oxide and vinyl halides (vinyl fl uoride, vinyl chloride, and vinyl bromide), vol 97. IARC, Lyon
93. Melnick RL, Sills RC (2001) Comparative carcinogenicity of 1,3-butadiene, isoprene and chloroprene in rats and mice. Chem Biol Interact 135-136:27-42 (Pubitemid 32530477)
94. Walker VE, Walker DM, Meng Q, McDonald JD, Scott BR, Selikop SK, Claffey DJ, Upton PB, Powley MW, Swenberg JA, Henderson RF, Committee HR (2009) Genotoxicity of 1,3- butadiene and its epoxy intermediate. Res Rep Health Eff Inst 144:3-79
95. Koturbash I, Scherhag A, Sorrentino J, Sexton K, Bodnar W, Tryndyak V, Latendresse JR, Swenberg JA, Beland FA, Pogribny IP, Rusyn I (2011) Epigenetic alterations in liver of C57BL/6J mice after short-term inhalational exposure to 1,3-butadiene. Environ Health Perspect 119:635-640
96. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T (2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 18:1251-1262 (Pubitemid 38720593)
97. Martens JH, O'Sullivan RJ, Braunschweig U, Opravil S, Radolf M, Steinlein P, Jenuwein T (2005) The pro fi le of repeat-associated histone lysine methylation states in the mouse epigenome. EMBO J 24:800-812 (Pubitemid 40396109)
98. Jenuwein Y (2006) The epigenetic magic of histone lysine methylation. FEBS J 273:3121-3135
99. Koturbash I, Scherhag A, Sorrentino J, Sexton K, Bodnar W, Swenberg JA, Beland FA, Pardo-Manuel Devillena F, Rusyn I, Pogribny IP (2011) Epigenetic mechanisms of mouse interstrain variability in genotoxicity of the environmental toxicant 1,3-butadiene. Toxicol Sci 122:448-456
100. Rusyn I, Gatti DM, Wilshire T, Kleeberger SR, Threadgill DW (2010) Toxicogenomics: population-based testing of drug and chemical safety in mouse models. Pharmacogenomics 11:1127-1136
101. IARC Monographs on the Evaluations of Carcinogenic Risks to Humans (2011) A review of human carcinogens, vol 100, Part A: Pharmaceuticals. IARC, Lyon
102. Li S, Washburn KA, Moore R, Uno T, Teng C, Newbold RR, McLachlan JA, Negishi M (1997) Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Res 57:4356-4359 (Pubitemid 27413446)
103. Li S, Hansman R, Newbold R, Davis B, McLachlan JA, Barrett JC (2003) Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. Mol Carcinog 38:78-84 (Pubitemid 37255143)
104. Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng RY, Medvedovic M, Ho SM (2008) Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 149:5922-5931
105. Sato K, Fukata H, Kogo Y, Ohgane J, Shiota K, Mori C (2009) Neonatal exposure to diethylstilbestrol alters expression of DNA methyltransferases and methylation of genomic DNA in the mouse uterus. Endocr J 56:131-139
106. Hsu PY, Detherage DE, Rodriguez BA, Liyanarachchi S, Weng YI, Zuo T, Liu J, Cheng AS, Huang TH (2009) Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res 69:5936-5945
107. Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, Kreipe H (2008) Epigenetic inactivation of microRNA gene has-mir-9-1 in human breast cancer. J Pathol 214:17-24
108. Jordan VC (2006) Tamoxifen (ICI146,474) as a target therapy to treat and prevent breast cancer. Br J Pharmacol 147:S269-S276 (Pubitemid 43077285)
109. Shang Y (2006) Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6:360-368
110. Wu H, Chen Y, Liang J, Shi B, Wu G, Zhang Y, Wang D, Li R, Yi X, Zhang H, Sun L, Shang Y (2005) Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438:981-987 (Pubitemid 43093965)
111. Wogan GN (1997) Review of the toxicology of tamoxifen. Semin Oncol 24:S87-S97
112. Phillips DH (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis 22:839-849
113. Gamboa da Costa G, McDaniel-Hamilton LP, Heflich RH, Margues MM, Beland FA (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22:130701315
114. Tryndyak VP, Muskhelishvili L, Kovalchuk O, Rodriguez-Juarez R, Churchwell MI, Ross SA, Beland FA, Pogribny IP (2006) Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 27:1713-1720 (Pubitemid 44288061)
115. Tryndyak VP, Kovalchuk O, Muskhelishvili L, Montgomery B, Rodriguez-Juarez R, Melnyk S, Ross SA, Beland FA, Pogribny IP (2007) Epigenetic reprogramming of liver cells in tamoxifen-induced rat hepatocarcinogenesis. Mol Carcinog 46:187-197 (Pubitemid 46399517)
116. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O (2007) Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 619:30-37 (Pubitemid 46602445)
117. Bachman AN, Phillips JM, Goodman JI (2006) Phenobarbital induces progressive patterns of GC-rich and gene-speci fi c altered DNA methylation in the liver of tumor-prone B6C3F1 mice. Toxicol Sci 91:393-405 (Pubitemid 43827292)
118. Phillips JM, Goodman JI (2009) Multiple genes exhibit Phenobarbital-induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors. Toxicol Sci 108:273-289
119. Lempiäinen H, Müller A, Brasa S, Teo SS, Roloff TC, Morawiec L, Zamurovic N, Vicart A, Funhoff E, Couttet P, Schübeler D, Grenet O, Marlowe J, Moggs J, Terranova R (2011) Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. PLoS One 6:e18216
120. Bucher JR, Shackelford CC, Haseman JK, Johnson JD, Kurtz PJ, Persing RL (1994) Carcinogenicity studies of oxazepam in mice. Fundam Appl Toxicol 23:280-297 (Pubitemid 24277250)
121. Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR (2003) Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis 24:757-770 (Pubitemid 36592411)
122. Lahousse SA, Hoenerhoff M, Collins J, Ton TV, Massinde T, Olson D, Rebolosso Y, Koujitani T, Tomer KB, Hong HH, Bucher J, Sills RC (2011) Gene expression and mutation assessment provide clues of genetic and epigenetic mechanisms in liver tumors of oxazepam-exposed mice. Vet Pathol 48:678-699
123. Ferguson LR, Philpott M (2008) Nutrition and mutagenesis. Annu Rev Nutr 28:313-329
124. IARC Monographs on the Evaluations of Carcinogenic Risks to Humans (2002) Some traditional herbal medicines, some mycotoxins, naphthalene and styrene, vol 82. IARC, Lyon
125. Wild CP, Gong YY (2010) Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 31:71-82
126. Knasmüller S, Bresgen N, Kassie F, Mersch-Sundermann V, Gelderblom W, Zöhrer E, Eckl PM (1997) Genotoxic effects of three Fusarium mycotoxins, fumonisin B1, moniliformin and vomitoxin in bacteria and primary cultures of rat hepatocytes. Mutat Res 391:39-48 (Pubitemid 27263450)
127. Wang JS, Groopman JD (1999) DNA damage by mycotoxins. Mutat Res 424:167-181 (Pubitemid 29101617)
128. Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ, Santella RM (2002) High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to a fl atoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 35:85-92
129. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY, Santella RM (2003) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to a fl atoxin B1-DNA adducts and the p53 mutations in hepatocellular carcinoma. Int J Cancer 103:440-444 (Pubitemid 36020217)
130. Su H, Zhao J, Xiong Y, Xu T, Zhou F, Yuan Y, Zhang Y, Zhuang SM (2008) Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res 641:27-35
131. Zhao W, Liu H, Liu W, Wu Y, Chen W, Jiang B, Zhou Y, Xue R, Luo C, Wang L, Jiang JD, Liu J (2006) Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol 28:1081-1088
132. Kouadio JH, Dano SD, Moukha S, Mobio TA, Creppy EE (2007) Effects of combinations of Fusarium mycotoxins on the inhibition of macromolecular synthesis, malondialdehyde levels, DNA methylation and fragmentation, and viability in Caco-2 cells. Toxicon 49:306-317 (Pubitemid 46185516)
133. Marin-Kuan M, Cavin C, Delatour T, Schilter B (2008) Ochratoxin A carcinogenicity involves a complex network of epigenetic mechanisms. Toxicon 52:195-202
134. Hu W, Feng Z, Tang M (2003) Preferential carcinogen-DNA adduct formation at codons 12 and 14 in the human K-ras gene and their possible mechanisms. Biochemistry 42: 10012-10023 (Pubitemid 37012877)
135. IARC Monographs on the Evaluations of Carcinogenic Risks to Humans (2011) A review of human carcinogens, vol 100, Part B: Biological agents. IARC, Lyon
136. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T (2006) High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12:989-995 (Pubitemid 43259882)
137. Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T (2009) The presence of methylation fi ngerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer 124:905-910
138. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M, Ushijima T (2010) In fl ammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 70:1430-1440
139. Shin CM, Kim N, Jung Y, Park JH, Kang GH, Kim JS, Jung HC, Song IS (2010) Role of Helicobacter pylori infection in aberrant DNA methylation along multistep gastric carcinogenesis. Cancer Sci 101:1337-1346
140. Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, Oda I, Gotoba T, Ushijima T (2010) Persistence of a component of DNA methylation in gastric mucosa after Helicobacter pylori eradication. J Gastroenterol 45:37-44
141. LeBaron MJ, Rasoulpour RJ, Klapacz J, Ellis-Hutchings RG, Hollnagel HM, Gollapudi BB (2010) Epigenetics and chemical safety assessment. Mutat Res 705:83-95
142. Huang YW, Kuo CT, Stoner K, Huang TH, Wang LS (2011) An overview of epigenetics and chemoprevention. FEBS Lett 585:2129-2136
143. Goodman JI, Augustine KA, Cunningham ML, Dixon D, Dragan YP, Falls JG, Rasoulpour RJ, Sills RC, Storer RD, Wolf DC, Pettit SD (2010) What do we need to know prior to thinking about incorporating an epigenetic evaluation into safety assessments? Toxicol Sci 116:375-381
144. Rasoulpour RJ, LeBaron MJ, Ellis-Hutchings RG, Klapacz J, Gpllapudi BB (2011) Epigenetic screening in product safety assessment: are we there yet? Toxicol Mech Methods 21:298-311
145. Kalari S, Pfeifer GP (2010) Identi fi cation of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 70:277-308